Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioCryst PharmaceuticalsBCRX -0.66%69 Days Inventory is 143.07 as of Jun. 2026, which is 74% below its 10-year median of 560.27. GuruFocus rates BCRX with a GF Score™ of 69/100 and a GF Value™ of $12.60 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 920 Drug Manufacturers companies, BioCryst Pharmaceuticals ranks better than 81.2% on this metric.
The historical rank and industry rank for BioCryst Pharmaceuticals's Days Inventory or its related term are showing as below:
BCRX'
s Days Inventory Range Over the Past 10 Years
Min: 96.68 Med: 560.27 Max: 2289.54
Current: 96.68
During the past 13 years, BioCryst Pharmaceuticals's highest Days Inventory was 2289.54. The lowest was 96.68. And the median was 560.27.
BCRX's Days Inventory is ranked better than 81.2% of 920
companies
in the Drug Manufacturers industry
Industry Median: 164.815
vs BCRX: 96.68
BioCryst Pharmaceuticals's Days Inventory
declined
from Jun. 2025 (194.32) to Jun. 2026 (143.07).
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioCryst Pharmaceuticals's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.64.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioCryst Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.03.
BioCryst Pharmaceuticals (NAS:BCRX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
BioCryst Pharmaceuticals's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioCryst Pharmaceuticals's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
BioCryst Pharmaceuticals Days Inventory Related Terms
BioCryst Pharmaceuticals Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCRX vs PBH, SUPN, AMLX: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCryst Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals (BCRX) has a Days Inventory of 143.07 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioCryst Pharmaceuticals and its competitors. This is 74% below median its historical median of 560.27. Over the past decade, BioCryst Pharmaceuticals' Days Inventory has ranged from 96.68 to 2,289.54. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #173 out of 920 companies in the Drug Manufacturers industry, placing it in the top 18.8%.
Is BioCryst Pharmaceuticals' Days Inventory too high?
BioCryst Pharmaceuticals' current Days Inventory of 143.07 is 74% below median its 10-year median of 560.27. Over the past 10 years, this metric has ranged from a low of 96.68 to a high of 2,289.54. The Drug Manufacturers industry median Days Inventory is 164.82. BioCryst Pharmaceuticals' value of 143.07 is 13.2% below this industry median. Based on the distribution chart, BioCryst Pharmaceuticals ranks #173 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Days Inventory compare to PBH and SUPN?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #173 out of 920 companies for Days Inventory. This places BioCryst Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.82. BioCryst Pharmaceuticals' value of 143.07 is 13.2% below this benchmark. Historically, BioCryst Pharmaceuticals' own Days Inventory has ranged from 96.68 to 2,289.54 over the past decade. While the company's 10-year median is 560.27 vs. the industry median of 164.82, BioCryst Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.82, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioCryst Pharmaceuticals's current Days Inventory of 143.07 is 13.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioCryst Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCryst Pharmaceuticals's current Days Inventory is 143.07, which is 74% below median its own 10-year median of 560.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.60, compared to a current price of $9.74 — trading 22.7% below its estimated fair value. The current Days Inventory is 143.07, which is 74% below median its 10-year median of 560.27 and 13.2% below the Drug Manufacturers industry median of 164.82. BioCryst Pharmaceuticals' overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Days Inventory is 143.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued.
The current stock price of $9.74 is trading 22.7% below its estimated GF Value™ of $12.60.
GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BCRX:
Days Inventory: 143.07 (74% below median its 10-year median of 560.27)
GF Value™: $12.60 vs. price of $9.74 (22.7% below fair value)
Industry Position: 13.2% below the Drug Manufacturers median (#173 of 920)
No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
69GF Score
Get the complete analysis for BCRX
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCRX has been successfully added to your 
